PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Bailing capsules (derived from C. sinensis) significantly improved forced expiratory volume in 1s (FEV1), FEV1/FVC ratio, and 6-min walk test (6MWT) results [PMID:39460586].
Bailing capsule significantly reduced the frequency of acute exacerbation of CB compared with placebo [PMID:39193337].
Adjunctive use of cordyceps or fermented products significantly improved C-reactive protein levels [PMID:32186018].
Used as a common ingredient for treatment, though a systematic review aimed to evaluate therapeutic and adverse effects [PMID:25519252].
Evaluated as an adjuvant immunosuppressive agent to assess graft rejection and survival rates [PMID:28137532].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 24716152 (2013) — A Systematic Review of the Mysterious Caterpillar Fungus Ophiocordyceps sinensis in Dong-ChongXiaCao ( Dōng Chóng Xià Cǎo) and Related Bioactive Ingredients. · Journal of traditional and complementary medicine
- 2.PMID: 29371523 (2017) — Entomopathogenicity and Biological Attributes of Himalayan Treasured Fungus Ophiocordyceps sinensis (Yarsagumba). · Journal of fungi (Basel, Switzerland)
- 3.PMID: 39519748 (2024) — Cordyceps Polysaccharides: A Review of Their Immunomodulatory Effects. · Molecules (Basel, Switzerland)
- 4.PMID: 32288794 (2013) — Properties of Cordyceps Sinensis: A review. · Journal of functional foods
- 5.PMID: 38048742 (2024)